Comparative aspects of triptans in treating migraine

Area of Science:

• Neurology
• Pharmacology

Background:

• Migraine treatment has been significantly advanced by triptans.
• Several new triptan formulations are nearing availability in the U.S.

Purpose of the Study:

• To compare the pharmacokinetic and clinical response differences among various triptans.
• To highlight how these differences enable individualized migraine treatment.

Main Methods:

• Comparative review of existing triptan formulations and their properties.
• Analysis of onset of action, efficacy, adverse effects, and half-life.

Main Results:

• Subcutaneous sumatriptan offers rapid onset and high efficacy but more adverse effects.
• Oral formulations like rizatriptan show strong early efficacy; rapidly dissolving wafers are available.
• Naratriptan and frovatriptan are suitable for prolonged attacks or prevention due to long half-lives and tolerability.
• Almotriptan demonstrates comparable efficacy to oral sumatriptan with potentially fewer side effects.
• Eletriptan (80 mg) shows high efficacy but may have dose-limiting side effects.

Conclusions:

• The diverse profiles of available triptans facilitate personalized migraine management.
• Treatment selection should consider patient-specific attack characteristics, tolerance, and preferences.